Posts by: Ines Martins, PhD

Ines Martins, PhD

Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.

May 30, 2017

FDA to Review Kite’s Application for CAR T-Cell Therapy to Treat Aggressive Non-Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration (FDA) has accepted for review the biologics license application (BLA) seeking the approval of axicabtagene ciloleucel (KTE-C19) for the treatment of refractory aggressive ... Read more

May 25, 2017May 25, 2017

Karyopharm to Present New Phase 2 Data on Selinexor in Advanced DLBCL Patients

News

Karyopharm Therapeutics will soon present interim data from a Phase 2b clinical trial evaluating selinexor (KPT-330), an oral selective inhibitor of the nuclear export compound, in patients with relapsed or refractory diffuse large ... Read more

May 24, 2017

Innate to Present New Data from Therapy Candidate for Cutaneous T-Cell Lymphoma

News

The Phase 1 trial evaluating IPH4102 in patients with relapsed or refractory cutaneous T-cell lymphoma has completed its dose escalation part and is preparing to initiate its cohort expansion part. ... Read more

May 22, 2017

Betalutin Trial for Non-Hodgkin’s Lymphoma Patients Opens New Expansion Cohort

News

The LYMRIT 37-01 Phase 1/2 trial assessing Betalutin in non-Hodgkin’s lymphoma patients will continue to evaluate Betalutin administered after pre-dosing with lilotomab in a Phase 2 expansion cohort of Arm 4. ... Read more

May 19, 2017May 19, 2017

DPX-Survivac to be Tested in Canada as Triple-combo Lymphoma Treatment

News

Patients with a certain type of lymphoma whose tumors are expressing the survivin protein may be able to participate in a Phase 2 Canadian clinical trial of Immunovaccine‘s cancer ... Read more

May 18, 2017

FDA Gives Copanlisib Priority Review for Treatment of Follicular Lymphoma

News

The U.S. Food and Drug Administration has granted priority review status to Bayer‘s new drug application of copanlisib for the treatment of refractory or relapsed follicular lymphoma patients who ... Read more

May 12, 2017May 12, 2017

Managed Access Program to Provide European Peripheral T-cell Lymphoma Patients Access to Beleodaq

News

Europeans with relapsed or refractory peripheral T-cell lymphoma (PTCL) who have no current alternative treatment options may soon get access to Onxeo‘s Beleodaq (belinostat), under a managed access program lauched ... Read more

May 9, 2017

Verastem to Present Long-term Findings on Duvelisib’s Ability to Counter Non-Hodgkin’s Lymphoma

News

Verastem will present long-term findings on duvelisib’s ability to combat non-Hodgkin’s lymphoma at the 14th International Conference on Malignant Lymphoma in Lugano, Switzerland, June 14-17. Forty-six of 129 lymphoma patients in the DYNAMO Phase 2 ... Read more

May 8, 2017May 8, 2017

Merck’s Keytruda Therapy for Certain Classical Hodgkin Lymphoma Patients Wins European Approval

News

The European Commission has approved the immune checkpoint inhibitor Keytruda (pembrolizumab) to treat certain Hodgkin lymphoma patients in 31 European countries, Merck announced. The approval applies to patients with relapsed or refractory ... Read more

May 1, 2017May 1, 2017

Epizyme’s Tazemetostat Receives FDA Fast Track Designation to Treat Follicular Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted Fast Track status to Epizyme‘s tazemetostat as a potential treatment for relapsed or refractory follicular lymphoma patients with or without EZH2 activating ... Read more

Pin It on Pinterest